Apotex Receives First U.S. FDA Tentative Approval for a Generic Version of Ozempic® (Semaglutide Injection) in Partnership with Orbicular
Apr 10, 2026Weston, Florida – April 10, 2026 — Apotex Corp. today announced it has received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for Semaglutide Injection, marking a significant milestone in expanding affordable access to complex peptide therapies for patients across the United States.
This approval reinforces Apotex's leadership in bringing high value, technically challenging medicines that help improve patient access and support a more sustainable healthcare system. It's further proof of the company's longstanding commitment to scientific excellence and advancing complex generics that can help reduce costs for patients and payers.
Developed through a strategic partnership with Orbicular Pharmaceutical Technologies, the Semaglutide Injection program is a result of sophisticated development capabilities, including advanced analytical characterization and deep process understanding.
"This is a clear demonstration of what true partnership can achieve," said Barry Fishman, Chief Corporate Development Officer, Apotex. "As a Force for Health, this milestone reflects Apotex’s leadership in bringing together complementary strengths, a shared purpose, and an unwavering commitment to execution excellence."
"Achieving technical equivalence for complex peptide products requires deep scientific rigor, advanced analytical precision, and a highly disciplined development approach," said Dr. M. S. Mohan, Managing Director, Orbicular Pharmaceutical Technologies. "We are proud to have supported Apotex in this important program. Their regulatory leadership coupled with Orbicular's development and execution excellence were central to securing FDA Tentative Approval."
The FDA Tentative Approval underscores the strength of Apotex's global development model and its ability to deliver complex generics that meet rigorous regulatory requirements. Upon becoming eligible for final approval, Apotex's Semaglutide Injection is expected to help broaden patient access to an important therapy area where affordability and availability remain critical.
About Apotex
Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to innovative medicines and health products for millions of people around the world, offering a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally—including in the United States, Mexico, and India—we are the largest Canadian based pharmaceutical company and a health partner of choice across the Americas for pharmaceutical licensing and product acquisitions.
Media contact: [email protected]
About Orbicular
Orbicular is a partnership driven, B2B specialty pharmaceutical company focused on designing, developing, and delivering complex generics and specialty pharmaceutical products. With integrated capabilities spanning development, advanced analytical characterization, regulatory strategy, and technology transfer, Orbicular enables partners to bring high-value, technically complex products to global markets.
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 18, 2026
Apotex Health Corp. announces closing of upsized bought deal secondary offering
Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").
-
Sep 15, 2026
Apotex Health Corp. announces $750 million bought deal secondary offering
Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.